Business Wire

Industry Leaders Business Wire and TrendKite Partner to Combine News Distribution and Advanced Media Analytics for a More Powerful Public Relations Solution

Del

Business Wire and TrendKite have entered into a reciprocal sales arrangement, enabling clients to leverage the industry’s most comprehensive news distribution platform and then gauge the effectiveness of their campaign using the advanced analytics of TrendKite’s Intelligent Communications Platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005104/en/

The agreement brings together two influential service providers serving the public relations industry: Business Wire, the global leader in press release distribution, and TrendKite, a startup that has upended the legacy monitoring industry with its technological innovation and data-driven approach to quantifying media outreach results.

Business Wire and TrendKite will offer select service offerings under the terms of the agreement.

TrendKite clients will have the opportunity to reach audiences worldwide via Business Wire, which provides access to dozens of international and national news agencies, as well as leading financial information platforms, news syndicators, content aggregation services and databases.

Business Wire clients will be able to take advantage of the TrendKite Intelligent Communications Platform to measure the effectiveness of their press releases and public relations campaigns and identify and target key journalists and influencers to pitch. TrendKite helps organizations make better data-informed decisions about their communications programs and measure the business impact and bottom line results of their earned media. TrendKite’s innovative services transform 4.7 million global sources into actionable intelligence with customized dashboards, interactive reports, social amplification, Google and Adobe Analytics integrations and PR Attribution, which assesses the true impact of a media mention by measuring site traffic influenced by earned media. Going a step further, TrendKite has created Pinpoint Contacts, an artificial intelligence-powered influencer and journalist database, to assist communicators in identifying relevant contacts.

“TrendKite is a forward-thinking company that is aligned with Business Wire’s perspective on the future of content delivery and monitoring solutions,” said Geff Scott, Business Wire’s chief executive officer. “Our relationship with TrendKite promises to bring value to clients of both companies, providing best-of-breed solutions that will create new industry standards.”

“Our customers rely on news distribution as part of their plan to take a story to market, but have trouble knowing if their press releases are gaining earned coverage that drives business results,” said Erik Huddleston, TrendKite’s chief executive officer. “Business Wire’s status as the industry leader, combined with their measurably superior results and their understanding of the earned media landscape, make them a natural partner for TrendKite and a high value for our customers.”

About Business Wire:

Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire to accurately distribute market-moving news and multimedia, host online newsrooms and IR websites, build content marketing platforms, generate social engagements and provide audience analysis that improves interaction with specified target markets. Founded in 1961, Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX Network. Business Wire has 29 offices worldwide to securely meet the varying needs of communications professionals and news consumers.

Learn more at services.BusinessWire.com and Tempo, the Business Wire resource for industry trends; follow updates on Twitter: @businesswire or on Facebook.

About TrendKite

Founded in 2012 in Austin, Texas, TrendKite is the Intelligent Communications Platform that puts earned media at the heart of the marketing mix. By harnessing artificial intelligence and big data analytics to optimize the impact public relations has on a brand’s reputation, website traffic and business goals, TrendKite is transforming the way the world views earned media.

As a venture backed, high traction startup, TrendKite is disrupting a huge existing market while helping companies like Nike, Google, Delta, SXSW and thousands more turn PR coverage into real business impact.

Click here to subscribe to Mobile Alerts for Business Wire .

Contact information

TrendKite
Lacey Miller
lacey@trendkite.com
or
Business Wire
Neil Hershberg, +1 212-752-9600, Ext. 1434

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 06:00:00 CETPressemelding

Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA25.3.2019 23:00:00 CETPressemelding

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

Game of Thrones Winter is Coming™ Launches Worldwide25.3.2019 23:00:00 CETPressemelding

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

bluebird bio Statement on European Regulatory Status of LentiGlobin™25.3.2019 22:40:00 CETPressemelding

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 20:30:00 CETPressemelding

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 19:50:00 CETPressemelding

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin